Aug 26, 2026 · 16 min
Solvonis bets £1.3 million on three clinical programmes
S11 Ep100: Midweek Takeaway with Anthony Tennyson, CEO of Solvonis Therapeutics plc (LSE: SVNS) #SVNS
Solvonis must turn a modest fundraise and investor skepticism into clinical, regulatory and commercial progress across its priority assets.
- 1The £1.3 million raise funds work on SVN001, SVN002 and SVN015, including European expansion and US regulatory preparation.
- 2Solvonis expects the next year to bring trial-partner updates, international enrollment and FDA feedback on SVN002.
- 3Anthony Tennyson acknowledges shareholder frustration over the down-round and argues that execution must now support valuation recovery.
Don't miss
Anthony Tennyson addresses shareholder disappointment over the down-round and says the company must now deliver against its business plan.
The brief
Solvonis Therapeutics CEO Anthony Tennyson discusses the company’s £1.3 million fundraise and how it will support three priority programmes: SVN001, SVN002 and SVN015.
The funding is intended to preserve strategic options, including potential European sites for SVN001 and preparation for US Phase IIb work, while regulatory milestones approach.
The conversation turns to collaboration with the National Institute on Drug Abuse, trial partners, international enrollment and anticipated FDA feedback for SVN002.
Tennyson says existing shareholders, new high-net-worth investors and an unnamed institution participated, while the institution’s investment amount remains undisclosed.
The sharpest tension is the down-round: Tennyson acknowledges shareholder disappointment and says execution, value creation and communication must now justify the company’s valuation.
What was said on this episode
11 statements · 11 positive
EU trial data could improve SVN001’s probability of EU marketing approval.
“what our hope would be that if we have EU data in the trial, it would increase the probability of an accepted marketing authorization or marketing approval in certain EU countries in due course.”
Listen at 3:59
Funding enables SVN002 bridge completion and FDA engagement for Phase 2B support.
“what this money enables us to do is to complete that process and then engage with the FDA, present the data to them and hopefully gain their support for a phase two program, but ideally a phase two B program.”
Listen at 4:57
Successful SVN015 work could position Solvonis to seek NIDA clinical-development funding.
“if that's successful, then what we would hope is we'd be able to be well positioned to apply for grant funding from NIDA to bring that program forward into clinic and into humans.”
Listen at 5:47
Adding EU data would significantly increase SVN001’s strategic optionality.
“by potentially adding in EU data, we increase the, let's just call it optionality for that program, I believe, significantly.”
Listen at 6:38
Spravato is forecast to reach approximately a $2 billion run rate for J&J.
“J&J Spravato is currently forecast, I think, to be about a $2 billion run rate business for J&J”
Listen at 7:24
Solvonis hopes to complete SVN002 FDA-related work before year-end.
“we would hope to have all of that done before the end of the year.”
Listen at 12:14
SVN015’s next tests, studies and results should occur during the rest of the year.
“And that should be through the course of the remainder of this year.”
Listen at 12:35
Tennyson believes Solvonis has a very good business and plan.
“We are, we have a, what I believe to be a very good business. with a very good plan.”
Listen at 14:05
Solvonis’s team should execute, create value and communicate progress.
“What I and the team now need to do is put our head down and execute, create value and communicate that to the street”
Listen at 14:24
New York-listed peers receive materially higher valuations than Solvonis’s London listing.
“when you look at our peers, listed in New York, where there is greater demand for these stories. There's a greater availability of capital for these stories. The valuations are of an order of magnitude different.”
Listen at 15:08
Solvonis should use raised capital prudently to execute and communicate potential value creation.
“We need to use that capital judiciously. to execute the business plan and to communicate out to investors so that current investors and potential new investors understand the value that we have the potential to create.”
Listen at 15:33
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Featuring
National Institute on Drug Abuse
United States
KetamineListen to the full episode and explore every guest, topic, and moment on PodLume.